【レポートの概要（一部）】
1. Report Overview
1.1 Biosimilars Overview
1.2 Biosimilars Market Segmentation
1.3 Why You Should Read this Report
1.4 How this Report Delivers
1.5 Main Questions Answered by this Report
1.6 Who is this Report for?
1.7 Research and Analysis Methods
1.8 Frequently Asked Questions (FAQ)
1.9 Some Associated Reports
1.10 About Visiongain
2. An Introduction to Biosimilars and Biosimilar Drug Development
2.1 What are Biologics?
2.1.1 Biologics can be Very Effective but also Very Expensive
2.1.2 Brief History of Biological Drug Development
2.1.3 Why are Biologics the Most Lucrative Products in the Global Pharmaceutical Market?
2.2 What are Biosimilars?
2.3 Brief History of Biosimilars
2.4 What are Interchangeable Biological Products and how do They Differ from Biosimilars?
2.4.1 FDA Guidelines on Prescription of Interchangeables vs Biosimilars
2.4.2 Where does the EMA Stand with Regard to Interchangeables?
2.4.3 Where do the EU5 and other European Countries Stand with Regard to Automatic Substitution?
2.4.4 Why Would Nations Oppose Automatic Substitution of Reference Biologics with Biosimilars?
2.5 Main Segments of the Overall Biosimilars Market
3. The Global Biosimilars Market 2016-2026
3.1 The Global Biosimilars Market
3.2 Biosimilars as a Share of the Biologics Market, 2014
3.2.1 Seven of the Top Ten Best-Selling Drugs are Biologics
3.2.2 Outlook for the Overall Biologics Market
3.3 Global Biosimilars Market Forecast, 2016-2026
3.4 What will Drive Growth in the Biosimilars Market?
3.4.1 Biosimilars Can Bring about Savings of Billions – $44bn for the US by 2024 and $33bn for Europe by 2020
3.4.2 Over $67bn Worth of Biologic Patents due to Expire by 2020
3.4.3 US Approves First Biosimilar – Zarxio. Will this Open the Floodgates? Interchangeability Can also Drive Growth
3.4.4 Other Developed and Emerging Markets Will also Provide Opportunities for Growth
3.4.5 Competitive Landscape Emerging for Biosimilars
3.5 What Factors can Restrain Sales Growth in the Biosimilars Market?
3.5.1 Complexity of Biologics Means that Biosimilar Development Faces Many Challenges
3.5.2 Opposition from Originator Companies and Patent Issues
3.5.3 Fragmentation in the Market as Many Companies Chase the Same Targets
3.5.4 The Threat of Biobetters and Next-Generation Biologics
3.6 Summary of the Drivers and Restraints for the Global Biosimilars Market
3.7 Global Biosimilars Market Forecast by Submarket, 2016-2026
3.7.1 Leading Segments in the Biosimilars Market
3.7.2 How Will the Composition of the Market Change Over the Next Ten Years?
4. Outlook for Biosimilars in Leading Developed Markets, 2016-2026
4.1 The Leading National Biosimilar Submarkets
4.2 National Submarket Forecasts 2016-2026
4.3 How will the Regional Composition of the Global Market Change from 2016-2026?
4.4 US Biosimilars Market Outlook 2016-2026
4.4.1 Status of the US Market in 2014 and 2015
4.4.2 FDA Finalises Three New Guidelines on 351(k) Applications in April 2015
4.4.2.1 The History of the US’ Biosimilar Guidelines
4.4.3 FDA Finally Releases Guidance on Biosimilar Naming in August 2015
4.4.4 Individual States Can Pass their Own Biosimilar Substitution Laws
4.4.5 US Biosimilars Market Forecast 2016-2026
4.5 The EU Biosimilar Market: History and Current Status
4.5.1 History of EMA Guidelines and Updates
4.5.2 Biosimilar Uptake in the Europe Varies between Nations
4.5.3 European Biosimilars Market Forecast, 2016-2026
4.5.4 Inflectra and Remsima in Europe – Demonstrates a Path for Other Biosimilar mAbs
4.5.5 German Biosimilar Market Outlook, 2016
4.5.5.1 German Biosimilar Market Forecast, 2016-2026
4.5.6 French Biosimilars Market Outlook, 2016
4.5.6.1 Biosimilar Substitution Passed but Requires Decrees to Come into Effect, Expected Sometime This Year
4.5.6.2 French Biosimilar Market Forecast, 2016-2026
4.5.7 UK Biosimilar Market Outlook, 2016
4.5.7.1 UK Biosimilar Market Forecast, 2016-2026
4.5.8 Italian Biosimilars Market Outlook, 2016
4.5.8.1 Italian Biosimilars Market Forecast, 2016-2026
4.5.9 Spanish Biosimilars Market Outlook, 2016
4.5.9.1 Spanish Biosimilar Market Forecast, 2016-2026
4.5.10 Biosimilar Regulation in Japan and Currently Approved Biosimilars
4.5.10.1 Differences between the European and Japanese Guidelines
4.5.10.2 Currently Approved Biosimilars in Japan
4.5.10.3 Japanese Biosimilar Market Forecast, 2016-2026
5. Outlook for Biosimilars in Emerging Markets, 2016-2026
5.1 China and India Lead Biosimilar Revenues
5.2 Leading Emerging Biosimilar Markets Forecast, 2016-2026
5.3 Chinese Biosimilars Market Outlook, 2016
5.3.1 China Publishes Final Guidelines for Biosimilars
5.3.2 Biosimilars Account for less than Half of Biotech Revenues in China
5.3.3 Chinese Biosimilars Market Forecast, 2016-2026
5.4 Indian Biosimilars Market Outlook, 2016
5.4.1 CDSCO Guidelines Released in 2012
5.4.2 Indian Biosimilars Market Forecast, 2016-2026
5.5 South Korea’s Established Biosimilar Guidelines
5.5.1 Currently Approved Biosimilars in South Korea, 2016
5.5.2 South Korean Biosimilars Market Forecast, 2016-2026
5.6 Russian Biosimilars Market Outlook and Forecast, 2016-2026
5.7 Brazilian Biosimilar Regulation
5.7.1 Government Eager to Promote Biosimilar Development, and Two Major Conglomerates, Bionovis and Orygen, are Racing to Produce Biosimilars
5.7.2 Brazilian Biosimilars Market Forecast, 2016-2026
6. Biosimilar Monoclonal Antibodies: Submarket Forecast and Pipeline, 2016-2026
6.1 MAbs as Part of the Overall Biologics Market in 2014
6.2 Monoclonal Antibodies (mAbs): Largest Biologic Submarket, with Individual Drugs Accumulating Multi-Billion Dollar Revenues
6.3 Biosimilar Monoclonal Antibodies Market and Submarkets Forecast, 2016-2026
6.4 Drivers for the Biosimilar Monoclonal Antibodies Market
6.4.1 New Launches of Biosimilar mAbs in Developed and Emerging Markets
6.4.2 Rising Incidence of Cancer will Drive Demand
6.4.3 The Need for Lower Cost Therapies
6.4.4 Partnering to Launch Biosimilar mAbs
6.5 Restraints for the Monoclonal Antibodies Market
6.5.1 Novel mAb Developers Choosing to Develop Biobetters and Next-Generation Therapies in Face of Biosimilar Competition
6.5.1.1 Hope for Biosimilars when Competing Against Next-Generation Therapies
6.5.2 Challenges in Antibody Development and Manufacturing
6.5.3 Patent Issues, Market Fragmentation and Perception of Biosimilars
6.6 Leading Targets for Biosimilar Development, 2016-2026
6.7 Biosimilar Rituximab
6.7.1 Rituxan: The First Anti-Cancer mAb
6.7.2 Approved Biosimilars and Rituxan Patent Expiry
6.7.2.1 Reditux (Dr. Reddy’s Laboratories): First Biosimilar Rituximab
6.7.2.2 MabTas (Intas Pharmaceutical): Another Indian Biosimilar
6.7.2.3 AcellBia (Biocad): The Leading Biosimilar Rituximab
6.7.2.4 Kikuzubam (PROBIOMED) – Faced Challenges
6.7.3 Biosimilar Rituximab Pipeline, 2016-2026
6.7.3.1 Terminated Developments
6.7.3.2 GP2013 (Sandoz): One of the Biggest Names in the Biosimilar Industry Throws its Hat into the Ring with Advanced Stage Candidate
6.7.3.3 BI 695500 (Boehringer Ingelheim)
6.7.3.4 MabionCD20 (Mabion): Focusing on Markets with High Demand
6.7.3.5 CT-P10 (Celltrion)
6.7.3.6 PF-05280586 (Pfizer)
6.7.4 Biosimilar Rituximab: Revenue Forecast 2016-2026
6.8 Biosimilar Infliximab
6.8.1 Remicade: Second Only to Humira
6.8.2 Approved Biosimilars and Remicade Patent Expiry: Uncertainty in the US after FDA Rejection
6.8.2.1 Inflectra and Remsima (Hospira and Celltrion)
6.8.2.2 Celltrion Speeds Ahead with US FDA Filing, and Inflectra Approved in Australia and Canada
6.8.2.3 Inflimab and BOW015 (Epirus Biopharmaceuticals and Ranbaxy Laboratories)
6.8.3 Biosimilar Infliximab Pipeline, 2015-2026
6.8.3.1 SB2 (Samsung Bioepis): Has been Filed for EU Approval and Shows Positive Phase 3 Results
6.8.3.2 NI-071 (Nichi-Iko): Advanced Stages
6.8.3.3 ABP 710 (Amgen) and BX2922 (BioXpress Therapeutics)
6.8.4 Biosimilar Infliximab: Revenue Forecast 2016-2026
6.9 Biosimilar Trastuzumab
6.9.1 Herceptin: Another Jewel in Roche’s Cancer mAb Portfolio
6.9.2 Approved Biosimilars and Herceptin Patent Expiry
6.9.2.1 Hertraz and CanMab (Mylan and Biocon): The First to Win Approval
6.9.2.2 Herzuma (Celltrion)
6.9.3 Biosimilar Trastuzumab Pipeline, 2015-2026
6.9.3.1 BCD-022 (Biocad): Leading Biosimilar Rituximab Developer Tries its Hand at Trastuzumab
6.9.3.2 ABP 980 (Amgen and Allergan): Phase 3
6.9.3.3 PF-05280014 (Pfizer): Phase 3
6.9.3.4 SB3 (Samsung Bioepis) and BX2318 (BioXpress Therapeutics)
6.9.4 Biosimilar Trastuzumab: Revenue Forecast 2016-2026
6.10 Biosimilar Adalimumab
6.10.1 Humira – The World’s Best-Selling Prescription Drug
6.10.2 Approved Biosimilars and Humira Patent Expiry
6.10.2.1 Exemptia (Zydus Cadila): The First Biosimilar Adalimumab
6.10.3 Biosimilar Adalimumab Pipeline, 2015-2026
6.10.3.1 ABP 501 (Amgen and Allergan): Positive Phase 3 Results Released
6.10.3.2 GP2017 (Sandoz): Phase 3
6.10.3.3 BI 695501 (Boehringer Ingelheim)
6.10.3.4 SB5 (Samsung Bioepis): Phase 3 Results
6.10.4 Biosimilar Adalimumab: Revenue Forecast 2016-2026
6.11 Biosimilar Bevacizumab
6.11.1 Avastin: High Revenues and Late Patent Expiry
6.11.2 Biosimilar Bevacizumab Pipeline, 2016-2026
6.11.2.1 BCD-021 (Biocad)
6.11.2.2 ABP 215 (Amgen and Allergan): Positive Phase 3 Results
6.11.2.3 BI 695502 (Boehringer Ingelheim): Phase 3
6.11.2.4 PF-06439535 (Pfizer): Phase 3
6.11.3 Biosimilar Bevacizumab: Revenue Forecast, 2016-2026
7. Biosimilar Fusion Proteins: Submarket Forecast and Pipeline, 2016-2026
7.1 Scientific Background
7.2 Differentiating Fusion Proteins
7.3 Fusion Proteins as Part of the Overall Biologics Market
7.4 Biosimilar Fusion Proteins Market Forecast, 2016-2026
7.5 Biosimilar Etanercept, 2016-2026
7.5.1 Enbrel is the Leading Fusion Protein
7.5.2 Enbrel Granted Extended Patent Protection in the US, Patent has Expired in EU
7.5.3 Multiple Biosimilars Available in Emerging Markets
7.5.3.1 Brenzys / SB4 (Merck and Samsung Bioepis): First Product Approval to Result from Biosimilar Collaboration
7.5.3.2 Yi Sai Pu (Shanghai CP Guojian Pharmaceutical) and Qiangke (Shanghai Celgen Biopharmaceutical)
7.5.3.3 Etacept (Cipla) and Intacept (Intas Pharmaceuticals)
7.5.3.4 Davictrel / HD-203 (Hanwha Chemical and Merck KGaA)
7.5.4 Biosimilar Etanercept Pipeline
7.5.5 GP2015 (Sandoz)
7.5.5.1 Sandoz Goes in Early: FDA Accepts Application for GP2015, Despite the Fact that Enbrel Patents are not due to Expire any time Soon
7.5.6 SB4 (Samsung Bioepis): EMA Accepts Application
7.5.6.1 Samsung Bioepis Releases Positive Phase 3 Data for SB4
7.5.7 CHS-0214 (Coherus Biosciences and Baxter)
7.5.8 TuNEX / ENIA11 (Mycenax Biotech / TSH Biopharm Corp): Phase 3 in Taiwan
7.5.9 LBEC0101 (LG Life Sciences): Phase 3
7.5.10 Biosimilar Etanercept: Revenue Forecast 2016-2026
7.6 Eylea and Biosimilar Aflibercept
7.7 Orencia and Biosimilar Abatacept
8. Biosimilar Insulin Submarket Outlook, 2016-2026
8.1 Insulin as Part of the Biological Drug Sector
8.2 30 Million People Expected to be Diagnosed with Diabetes by 2030
8.3 Approved Insulin Biosimilars
8.4 Abasaglar / Basaglar / Insulin Glargine BS – The First Insulin Biosimilars to be Approved in Developed Markets
8.5 EMA Releases Finalised Insulin Biosimilars Guideline
8.6 Basaglar Delayed in the US until End of 2016
8.7 Biosimilar Insulin Market and Submarkets Forecast, 2016-2026
8.8 Biosimilar Human Insulin Submarket, 2016-2026
8.8.1 A Submarket Mostly Restricted to Emerging Markets?
8.8.2 Biosimilar Human Insulin in China
8.8.3 Biosimilar Human Insulin in India
8.8.3.1 Wockhardt and Biocon – Given up on their Desire to Target the US and Europe?
8.8.4 Biosimilar Human Insulin in Russia
8.8.5 Biosimilar Human Insulin Submarket Forecast, 2016-2026
8.9 Biosimilar Insulin Analogues Submarket, 2016-2026
8.9.1 Available Biologic Insulin Analogues – Sanofi’s Lantus Tops Revenues
8.9.2 Insulin Glargine in the Main Biosimilar Target
8.9.2.1 Limited Development for the Other Targets
8.9.3 Insulin Market Leaders are Developing Ultra-Rapid Acting Insulin Analogues
8.9.3.1 Ultra-Long Acting Insulin also in Development
8.9.4 Mylan Partners with Biocon for Insulin Analogues
8.9.5 Biosimilar Insulin Analogue Revenue Forecast, 2016-2026
8.10 Biosimilar Insulin Glargine
8.10.1 Biosimilars in India and China
8.10.2 Biosimilar Insulin Glargine Pipeline
8.10.2.1 MK-1293 (Merck / Samsung Bioepis)
8.10.2.2 Mylan’s Insulin Glargine (Mylan and Biocon)
8.10.3 Biosimilar Insulin Glargine: Revenue Forecast, 2016-2026
8.11 Biosimilar Insulin Lispro
8.11.1 One Biosimilar is Currently Available – Prandlin
8.11.2 Much Smaller Pipeline than for Insulin Glargine
8.11.3 Biosimilar Insulin Lispro: Revenue Forecast, 2016-2026
9. Biosimilar Erythropoietins Submarket Outlook, 2016-2026
9.1 Three Products Lead the Biologic EPO Therapy Market
9.2 Safety Concerns for Erythropoietin-Stimulating Agents
9.3 The Challenge from Oral Therapies is Coming
9.4 Treating Anaemia in Patients with CKD – the Leading Use of EPO Therapies
9.5 Biosimilar Epoetin Approvals in Europe
9.6 Epoetin Alfa Pipeline for the European Market
9.7 Trends in Uptake for Biosimilar Epoetins in Europe
9.8 Epoetin Alfa Pipeline for the US – Companies Preparing for Launch
9.8.1 Pfizer’s Retacrit Delayed after Response Letter from FDA
9.8.2 Binocrit / HX575 has Completed Trials
9.9 Biosimilar Epoetin in Japan
9.10 Biosimilar Epoetin in South Korea
9.11 Biosimilar Epoetin in India and China
9.12 Second-Generation EPO Biosimilars
9.13 No Mircera Biosimilars in Clinical Development
9.14 Biosimilar EPO Market Forecast, 2016-2026
10. Biosimilar G-CSF Submarket Outlook, 2016-2026
10.1 Amgen Leads the Branded Biologic G-CSF Market
10.2 Teva Launches Long-Acting Pegfilgrastim
10.3 Selected Filgrastim Biosimilars Approved Worldwide
10.3.1 The European G-CSF Biosimilars Market
10.3.1.1 Trends in Biosimilar Uptake Across Europe
10.3.2 Tevagrastim (Teva): The First Biosimilar in Europe, Launched as Granix in the US
10.3.3 Nivestim (Hospira – Pfizer)
10.3.4 Zarzio (Sandoz): The Most Prescribed Biosimilar Therapy in Europe
10.3.5 Zarxio Becomes the First Biosimilar to be Approved in the US, Launched in September
10.3.6 Apotex: FDA has Accepted Applications for both its Biosimilar Filgrastim, and its Biosimilar Pegfilgrastim
10.3.7 Multiple Launches in Japan in Recent Years
10.3.8 Biosimilar Filgrastim and Pegfilgrastim in India
10.3.9 Biosimilars in Russia, China and Other Emerging Markets
10.4 Biosimilar G-CSF Market Forecast, 2016-2026
11. Biosimilar Interferons Submarket Outlook, 2016-2026
11.1 Interferons: Key Antiviral and MS Therapies Since the 1990s
11.2 Leading Interferon Brands
11.3 Competition for the Multiple Sclerosis Market – Challenges for Interferon Beta Therapies
11.4 All-Oral Regimens will Challenge Interferon Alfa Therapy
11.4.1 However Oral Therapies will be Expensive
11.5 There are no Approved Biosimilars in Developed Markets
11.6 Biosimilar Interferon Market Forecast, 2016-2026
11.7 Biosimilar Interferon Alfa
11.7.1 Biosimilar Interferon Alfa – a Common Target in Developing Countries, Leading to Fragmented Markets
11.7.2 Biosimilar Peginterferon Alfa
11.7.3 Hepatitis Treatment Rates are Low
11.7.4 Biosimilar Interferon Alfa Submarket Forecast, 2016-2026
11.8 Biosimilar Interferon Beta
11.8.1 Biosimilars are Well-Established in Emerging Markets
11.8.2 Biosimilar Interferon Beta Pipeline
11.8.3 EMA Guidance
11.8.4 Long-Acting Interferon Beta
11.8.5 Biosimilar Interferon Beta Submarket Forecast, 2016-2026
12. Biosimilar Recombinant Hormones Submarket Outlook, 2016-2026
12.1 Human Growth Hormone: First Extracted in 1958
12.2 Biologic Growth Hormone Market in 2014 – Novo Nordisk and Pfizer Dominate
12.2.1 Novo Nordisk Aiming to Retain Dominance Through FlexPro Device and NN8640 Somatropin Candidate
12.3 Biosimilar Growth Hormones
12.3.1 Omnitrope – Well Established in Developed Markets
12.4 Multiple Biosimilars Available Worldwide
12.4.1 Biosimilars Growth Hormones Outside of Asia
12.4.2 Biosimilar Growth Hormones in Asia
12.4.3 Biosimilar Uptake Varies by Region
12.5 Biosimilar Growth Hormones Market Forecast, 2016-2026
12.6 Fertility Hormones
12.6.1 Two Products Lead the Branded Fertility Hormone Market
12.6.2 Long-Acting Follicle Stimulating Hormone (FSH)
12.6.3 Branded Fertility Hormones Market Outlook
12.6.4 Available Biosimilar Fertility Hormones
12.6.5 Biosimilars Approved in Europe
12.6.5.1 Ovaleap (Teva)
12.6.5.2 Befomla (Finox Biotech) Approved in Europe, Undergoing Phase 3 for US
12.6.6 Rising Infertility to Drive Demand to 2026
12.6.7 Biosimilar Fertility Hormones Market Forecast, 2016-2026
13. Biosimilars: Qualitative Analysis and Industry Trends
13.1 SWOT Analysis of the Biosimilars Market
13.2 Biosimilars Market: Strengths
13.2.1 Biosimilars Can Offer Huge Cost Savings
13.2.2 The US has Finally Joined the Global Biosimilars Market
13.2.3 Biosimilars are Already Well-Established in Many National Markets
13.2.4 Outsourcing Offers the Chance for Further Cost Savings
13.3 Biosimilars Market: Weaknesses
13.3.1 Biosimilars are High Cost to Develop and Manufacture
13.3.2 Complexity Means that Development Timelines are Long
13.3.3 Uptake for Biosimilars Varies and is Low in Some Regions
13.4 Biosimilars Market: Opportunities
13.4.1 Blockbuster Biologics Face Patent Expiry
13.4.2 Rising Disease Prevalence
13.4.3 Licensing Agreements for Biosimilars
13.5 Threats
13.5.1 Biobetters and Next-Generation Biologics
13.5.2 Patent Issues and Product Life Cycle Management from Originator Companies
13.5.3 Fragmentation in the Market
13.5.4 Long Market and Data Exclusivity Periods
13.5.5 Biosimilars Require Marketing and Education
14. Research Interviews from Our Survey
14.1 Interview with PROBIOMED
14.1.1 Introduction to PROBIOMED
14.1.2 PROBIOMED’s Most Prominent Biosimilars and its Future Pipeline
14.1.3 Withdrawal of Kikuzubam and Changes in Mexican Biosimilar Regulation
14.1.4 On Standing out from the Competition
14.1.5 On How the Biosimilars Market will Develop over the Next Ten Years and its Main Strengths
14.2 Interview with Dr Ralph Warsinsky, Executive Director of Product Communications at Boehringer Ingelheim
14.2.1 On Boehringer Ingelheim’s Current Biosimilar Pipeline and its Reasons for Entering the Biosimilars Space
14.2.2 On Boehringer Ingelheim’s Track Record with Biopharmaceuticals and the Factors Needed to Become Successful in the Biosimilars Industry
14.2.3 Advantages over Competitors and Thoughts on the US Market
15. Conclusions from Visiongain’s Research and Analysis
15.1 Rapid Growth Expected for this High-Potential Market
15.2 Biosimilar Monoclonal Antibodies to be the Fastest Growing Segment
15.3 A Range of Factors Will Stimulate Demand
15.4 Challenges Remain in Developing and Successfully Launching Biosimilars
【レポート販売概要】
■ タイトル：バイオシミラーおよび後発生物製剤の世界市場動向・研究開発・売上予測：MAbs、融合蛋白質、インスリン、G-CSF、エリトロポエチン、インターフェロン、成長ホルモン、生殖ホルモン■ 英文：Biosimilars and Follow-On Biologics’ Trends, R&D and Revenue Forecasts 2016-2026 : Assess Prospects for MAbs, Fusion Proteins, Insulin, G-CSF, Erythropoietin, Interferons, Growth and Fertility Hormones
■ 発行日：2016年2月
■ 調査会社：visiongain
■ 商品コード：VGAIN6022514
■ 調査対象地域：グローバル
- 冷凍冷蔵機器用圧縮機（コンプレッサ）の世界市場2017-2021ABSTRACTAbout Refrigerant Compressors Refrigerant compressors are utilized in equipment by large-scale facilities for heat pumping, air conditioning, and refrigeration applications. Refrigerant compressors increase the temperature of the low-pressure gas by utilizing compression, while simultaneously removing vapor from the evaporator. Refrigerant compressors form the heart of refrigeration and HV …
- たばこ製造・販売企業分析：Indian Tobacco Corporation (ITC)Synopsis This report provides a unique and comprehensive analysis of the company Global, Regional and National Tobacco Players: Indian Tobacco Corporation (ITC), including the corporate profile, organisation structure, financial data, and competitive positioning. The analysis also details the organisation's history, merger and acquisition activity, licensing agreements, brand portfolio, as well as …
- 空気質監視の世界市場：固定ガス、携帯型モニター、粉じん・微粒子モニタ、AQMステーションThe global air quality monitoring market is expected to reach USD 5.64 Billion by 2021, at a CAGR of 8.5% from 2016 to 2021. A number of factors such as supportive government regulations for effective air pollution monitoring and control, ongoing government initiatives towards the development of environment-friendly industries, increasing public-private funding for effective air pollution monitori …
- Ultrasound Systems Market to 2019 – Technological Advancements, Wide Applications and Device Portability to Drive Future GrowthUltrasound Systems Market to 2019 - Technological Advancements, Wide Applications and Device Portability to Drive Future Growth Summary GBI Research’s “Ultrasound Systems Market to 2019 - Technological Advancements, Wide Applications and Device Portability to Drive Future Growth” report examines the market, competitive landscape, and trends for the following two ultrasound systems market segments: …
- 指紋センサの世界市場：スワイプセンサ、エリアセンサIn the present market scenario, security is one of the major issues of concern for various industry verticals such as banking, healthcare, defense, electronic gadgets, and government. This is due to the growing demand for secure & simplified access control and growing rate of unethical practices in various ,sectors, such as hacking of bank accounts, misuse of users’, , and so on. Security concerns …
- 世界のジオシンセティック市場：ジオテキスタイル、ジオメンブレンなどGeosynthetics are defined as polymeric materials used in engineering applications such as civil construction and environmental protection projects (such as landfill). The polymer materials used for this are generally polypropylene, polyethylene, and polyester. Geosynthetic materials are available in various sizes, strengths, and textures. Based on physical characteristics and subsequent applicatio …
- 世界のレーザーホログラフィディスプレイ市場2015The Global Laser Holographic Display Industry 2015 Market Research Report is a professional and in-depth study on the current state of the Laser Holographic Display industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Laser Holographic Display market analysis is provided for the international markets in …
- 除毛用製品の世界市場：除毛器、除毛クリーム、除毛ワックスAbout the Depilatory Products Market With more women entering the global workforce, the demand for and the affordability of depilatory products have increased. The rising numbers of salons and spas also increase product use. The following methods are commonly used for hair removal and there are many products to make the task easy. • Shaving • Creams • Waxing • Sugaring • Laser treatment • Electrol …
- ピクルス（漬物）の世界市場2016-2020About the Pickles Market Pickles serve as taste enhancers and are usually consumed with meals. In certain cuisines, such as sushi, they are used to refresh the palate between courses. They are also used as toppings for foods such as sandwiches, hamburgers, and hotdogs. Certain pickle varieties such as garlic, ginger, and olive are known for their health benefits. In addition, consumers also increa …
- Acetovanilloneの世界市場Acetovanillone (CAS 498-02-2) Market Research Report 2013 presents comprehensive data on acetovanillone markets globally and regionally (Europe, Asia, North America etc.) The Acetovanillone (CAS 498-02-2) Market Research Report 2013 includes acetovanillone description, covers its application areas and related patterns. It overviews acetovanillone market, names acetovanillone producers and indicate …
- 世界のデジタルマーケティングソフトウェア市場動向The digital marketing software industry, which is presently at a blooming stage, holds huge potential for growth in the coming years. A need for digital marketing software is developing due to the growing digital marketing proportion in overall marketing budget of organizations. It is used to overcome the backlogs like large volume of unstructured data. It assists companies with B2B and B2C market …
- ヘリコプタブレードの世界市場2016-2020About Helicopter Blades Helicopter blades are essential components of a rotorcraft as they are responsible for effective aerodynamic forces which provide airworthiness. Therefore, their manufacturing process and operations are closely monitored by regulatory bodies through stringent regulations. Factors that influence the global civil helicopter market are aircraft utilization, global fleet size, …
- グローバル建物用断熱市場（2014-2018）About Global Insulation Market Building insulation regulates the heat generated inside buildings. Insulation materials help control the heat that is dissipated through conduction, convection, and radiation. Apart from their unique thermal properties, insulation materials also provide protection against sound, fire, and impact. TechNavio's analysts forecast the Global Insulation market will grow at …
- 血友病A及びB：企業と競争環境PharmaPoint: Hemophilia A and B - Current and Future Players Summary GlobalData has released its pharma report, “PharmaPoint: Hemophilia A and B - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Hemophilia A and B Market. The report identifies and analyses the key companies shaping and driving the gl …
- 医療用エクソスケルトンの世界市場：コンポーネント別（ソフトウェア、ハードウェア）、タイプ別（パッシブ、電動）、四肢部位別（下肢、上肢）、モビリティ別（可動、定置）、地域別予測Global Medical Exoskeleton Market to reach USD 1.03 billion by 2025. Global Medical Exoskeleton Market valued approximately USD 64 million in 2016 is forecasted to grow with a healthy growth rate of more than 36.2% over the forecast period 2018-2025. The major factors speculated to augment the markets are rising insurance coverage for medical exoskeletons and rising number of people with physical …
